China Betaferon Adherence, Coping and Nurse Support Study

Bayer

Status: Completed

Conditions: Multiple Sclerosis, Chronic Progressive

Treatments: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT01436838

BF1110CN (Other Identifier)

15916

Details and patient eligibility

About

Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.

Enrollment: 110 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients

• Having Betaferon treatment, including patients who are

  • First time using; or
  • Re-staring; or
  • Switching from other diseases modifying drugs (DMDs)

Exclusion criteria

• Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).

Trial design

110 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta-1b (Betaseron, BAY86-5046)